<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20241001063232N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-10-20</date_registration>
      <primary_sponsor>University of Lahore</primary_sponsor>
      <public_title>Proprioceptive neuromuscular facilitation in adjunct to mirror therapy on clinical recovery ,synkinesis and quality of life in patients with Bell's palsy</public_title>
      <acronym></acronym>
      <scientific_title>Proprioceptive neuromuscular facilitation in adjunct to mirror therapy on clinical recovery ,synkinesis and quality of life in patients with Bell's palsy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-02-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/79640</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization will be used by one of the research team members who will be blinded and not involve in patients recruitment or assessment or data analysis. Participants are randomly allocated into two groups through lottery method, Blinding description: This is single blinded study in which accessor will be unaware of treatment.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Bell palsy is an idiopathic peripheral nerve disorder involving the facial nerve (ie, cranial nerve VII) and manifesting as acute, ipsilateral facial muscle weakness. It affects individuals across multiple ages and both sexes, with an annual incidence ranging from 11.5 to 53.3 per 100,000 persons across multiple populations..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The participants randomly allocated in Group A will be received the PNF with mirror therapy (MT). After electrical muscle stimulation proprioceptive neuromuscular facilitation techniques (PNF) will be done. Proprioceptive neuromuscular facilitation techniques (PNF) that will be used are rhythmic initiation and repeated stretch as shown in figure 1 using mirror. Participants will be sit upright, maintaining good posture. Keep mirror at eye level. With both eyes open, look into mirror with only on unaffected side. Patients will be observed the mirror reflection for one to two minutes, then trying to visualize the mirror image as the affected side. Once the subject will be engaged with mirror side then proprioceptive exercises will be performed. Intervention 2: Intervention group: In group B patients will be received PNF without mirror therapy (MT). After electrical muscle stimulation, proprioceptive neuromuscular facilitation techniques (PNF) will be done. Proprioceptive neuromuscular facilitation techniques (PNF) that will be used are rhythmic initiation and repeated stretch.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Demographic data and data related to final outcome will be shared by maintaining the confidentially

When:
Data will be available after the publication of findings till six months

To whom:
Sadia Ghafoor

Conditions:
For research purpose

Where to obtain:
To the corresponding author of the study , Sadia Ghafoor  and can contact on +92 304 787995 , sgrana1@outlook.com

How to obtain:
Open access and there is the traditional public data release where anyone can get access to the data

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sadia Ghafoor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>1-kn Defence Road near Bhuptian Chowk Lahore</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>55150</zip>
        <telephone>+92 304 787995</telephone>
        <email>sgrana14@outlook.com</email>
        <affiliation>University of Lahore</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sadia Ghafoor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>1 km Defence road near Bhuptian Chowk Lahore</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>55150</zip>
        <telephone>+92 304 787995</telephone>
        <email>sgrana14@outlook.com</email>
        <affiliation>University of Lahore</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Aged between 25-50 years
Both Male and females
Patients with unilateral Bells’ Palsy diagnosed by neurologist
Patients with moderate to severe Bell’s palsy (House-Brackmann Scale facial nerve grading 3 and 4)
Patients with unilateral bell’s palsy</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with Autoimmune/ hematologic disease
Patients with Inflammatory disease(e.g. Rheumatoid arthritis)
Patients with any neurodegenerative disease
Patients with cognitive impairments</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G51.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Bell's palsy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The participants randomly allocated in Group A will be received the PNF with mirror therapy (MT). After electrical muscle stimulation proprioceptive neuromuscular facilitation techniques (PNF) will be done. Proprioceptive neuromuscular facilitation techniques (PNF) that will be used are rhythmic initiation and repeated stretch as shown in figure 1 using mirror. Participants will be sit upright, maintaining good posture. Keep mirror at eye level. With both eyes open, look into mirror with only on unaffected side. Patients will be observed the mirror reflection for one to two minutes, then trying to visualize the mirror image as the affected side. Once the subject will be engaged with mirror side then proprioceptive exercises will be performed.</i_keyword>
      <i_keyword>Intervention group: In group B patients will be received PNF without mirror therapy (MT). After electrical muscle stimulation, proprioceptive neuromuscular facilitation techniques (PNF) will be done. Proprioceptive neuromuscular facilitation techniques (PNF) that will be used are rhythmic initiation and repeated stretch.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The House-Brackmann Scale (HBS) is one of several analysis tools that have been developed to quantify facial function and provide reproducible information in measuring the global degree of paresis and paralysis. Timepoint: 9th weeks. Method of measurement: It is a widely accepted system and is simple, sensitive, accurate, and reliable, grading facial function in 6 stages, from normal (HB I) to total paralysis (HB VI).</prim_outcome>
      <prim_outcome>The Synkinesis Assessment Questionnaire comprises nine questions and is a valid and reliable measurement for synkinesis. It correlates well with the synkinesis aspect of FGS. Timepoint: 9th week. Method of measurement: Chuang et al. introduced a four-category classification: I) Good smile with mild synkinesis, II) Acceptable smile with moderate to severe synkinesis, III) Unacceptable smile with severe synkinesis, and IV) Poor smile with mild synkinesis.</prim_outcome>
      <prim_outcome>The Facial Clinimetric Evaluation Scale (FaCE) is a patient-based instrument that measures facial impairment and disability in evaluating quality-of-life issues that are caused by facial disability. Timepoint: 9th weeks. Method of measurement: This questionnaire consists of 15 questions on a 5-point Likert Scale and comprises 6 domains: facial movement, facial comfort, oral function, eye comfort, lacrimal control, and social function. Total and domain scores range from 0 (worst) to 100 (best). This scale has been used in several studies on patient satisfaction following treatment.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Lahore</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-03-07</approval_date>
        <contact_name>Research Ethics Committee of University of Lahore</contact_name>
        <contact_address>University of Lahore Teaching Hospital Lahore , Punjab , Pakistan Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
